CD5 and diffuse large B-cell lymphoma: We compared the baseline clinical characteristics of 223 DLBCL patients stratified based on T-cell marker status (Table 4): T-cell marker-negative DLBCL (n = 175; 78%), CD5-positive DLBCL (n = 31; 14%), and non-CD5-T-cell-marker-positive DLBCL (n = 17; 8%).